If that were true, Zantrene would be approved in AML and being marketed now. I don't think we can think of AML as a sure thing, derisking RAC.
In fact, I'd be annoyed if the company was sitting on a drug which they could easily get approval and sales for. Because it would generate revenue and fund the other clinical indications.
Ann: Race continues Board renewal - appoints new Chair, page-93
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $284.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $119.1K | 71.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7995 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 400 | 1 |
View Market Depth
| Last trade - 13.25pm 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |